Prospects for oral replicating adenovirus-vectored vaccines

Research output: Contribution to journalArticle

Abstract

Orally delivered replicating adenovirus (Ad) vaccines have been used for decades to prevent adenovirus serotype 4 and 7 respiratory illness in military recruits, demonstrating exemplary safety and high efficacy. That experience suggests that oral administration of live recombinant Ads (rAds) holds promise for immunization against other infectious diseases, including those that have been refractory to traditional vaccination methods. Live rAds can express intact antigens from free-standing transgenes during replication in infected cells. Alternatively, antigenic epitopes can be displayed on the rAd capsid itself, allowing presentation of the epitope to the immune system both prior to and during replication of the virus. Such capsid-display rAds offer a novel vaccine approach that could be used either independently of or in combination with transgene expression strategies to provide a new tool in the search for protection from infectious disease.

Original languageEnglish (US)
Pages (from-to)3236-3243
Number of pages8
JournalVaccine
Volume31
Issue number32
DOIs
StatePublished - 2013

Fingerprint

Adenovirus Vaccines
capsid
Capsid
Adenoviridae
Transgenes
epitopes
infectious diseases
transgenes
Communicable Diseases
Epitopes
mouth
vaccines
Virus Replication
virus replication
oral administration
Oral Administration
immune system
Immune System
Immunization
immunization

Keywords

  • Capsid-display
  • Hexon
  • Oral administration
  • Replicating adenovirus vectors
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Prospects for oral replicating adenovirus-vectored vaccines. / Deal, Cailin; Pekosz, Andrew; Ketner, Gary W.

In: Vaccine, Vol. 31, No. 32, 2013, p. 3236-3243.

Research output: Contribution to journalArticle

@article{5aa64cba0b61436e86272974563ff34f,
title = "Prospects for oral replicating adenovirus-vectored vaccines",
abstract = "Orally delivered replicating adenovirus (Ad) vaccines have been used for decades to prevent adenovirus serotype 4 and 7 respiratory illness in military recruits, demonstrating exemplary safety and high efficacy. That experience suggests that oral administration of live recombinant Ads (rAds) holds promise for immunization against other infectious diseases, including those that have been refractory to traditional vaccination methods. Live rAds can express intact antigens from free-standing transgenes during replication in infected cells. Alternatively, antigenic epitopes can be displayed on the rAd capsid itself, allowing presentation of the epitope to the immune system both prior to and during replication of the virus. Such capsid-display rAds offer a novel vaccine approach that could be used either independently of or in combination with transgene expression strategies to provide a new tool in the search for protection from infectious disease.",
keywords = "Capsid-display, Hexon, Oral administration, Replicating adenovirus vectors, Vaccine",
author = "Cailin Deal and Andrew Pekosz and Ketner, {Gary W}",
year = "2013",
doi = "10.1016/j.vaccine.2013.05.016",
language = "English (US)",
volume = "31",
pages = "3236--3243",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "32",

}

TY - JOUR

T1 - Prospects for oral replicating adenovirus-vectored vaccines

AU - Deal, Cailin

AU - Pekosz, Andrew

AU - Ketner, Gary W

PY - 2013

Y1 - 2013

N2 - Orally delivered replicating adenovirus (Ad) vaccines have been used for decades to prevent adenovirus serotype 4 and 7 respiratory illness in military recruits, demonstrating exemplary safety and high efficacy. That experience suggests that oral administration of live recombinant Ads (rAds) holds promise for immunization against other infectious diseases, including those that have been refractory to traditional vaccination methods. Live rAds can express intact antigens from free-standing transgenes during replication in infected cells. Alternatively, antigenic epitopes can be displayed on the rAd capsid itself, allowing presentation of the epitope to the immune system both prior to and during replication of the virus. Such capsid-display rAds offer a novel vaccine approach that could be used either independently of or in combination with transgene expression strategies to provide a new tool in the search for protection from infectious disease.

AB - Orally delivered replicating adenovirus (Ad) vaccines have been used for decades to prevent adenovirus serotype 4 and 7 respiratory illness in military recruits, demonstrating exemplary safety and high efficacy. That experience suggests that oral administration of live recombinant Ads (rAds) holds promise for immunization against other infectious diseases, including those that have been refractory to traditional vaccination methods. Live rAds can express intact antigens from free-standing transgenes during replication in infected cells. Alternatively, antigenic epitopes can be displayed on the rAd capsid itself, allowing presentation of the epitope to the immune system both prior to and during replication of the virus. Such capsid-display rAds offer a novel vaccine approach that could be used either independently of or in combination with transgene expression strategies to provide a new tool in the search for protection from infectious disease.

KW - Capsid-display

KW - Hexon

KW - Oral administration

KW - Replicating adenovirus vectors

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84879459516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879459516&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.05.016

DO - 10.1016/j.vaccine.2013.05.016

M3 - Article

C2 - 23707160

AN - SCOPUS:84879459516

VL - 31

SP - 3236

EP - 3243

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -